What is this study about?
This study tracks antibiotic resistance in patients with cirrhosis who develop bacterial infections. Cirrhosis is a condition where the liver is severely scarred, and people with cirrhosis are at high risk for serious bacterial infections.
Why is this study important?
Bacterial infections are common in patients with cirrhosis, affecting 25-46% of those who are hospital…
What is this study about?
This study tracks antibiotic resistance in patients with cirrhosis who develop bacterial infections. Cirrhosis is a condition where the liver is severely scarred, and people with cirrhosis are at high risk for serious bacterial infections.
Why is this study important?
Bacterial infections are common in patients with cirrhosis, affecting 25-46% of those who are hospitalized. These infections can be life-threatening, with 1 in 4 patients dying from complications. Many of these infections are becoming harder to treat because the bacteria are resistant to antibiotics. Infections caused by resistant bacteria are increasing, which makes finding the right antibiotic quickly even more difficult.
In other regions of the world, guidelines exist to help doctors choose the right antibiotics for cirrhosis patients. However, in Latin America, we don't have specific guidelines for our region, and doctors currently rely on recommendations from the U.S. or Europe. These guidelines may not reflect the local patterns of bacterial infections and resistance we see here.
What is the goal of this study?
The main goal of this study is to create a long-term system to track how bacteria respond to antibiotics in patients with cirrhosis in Latin America. By collecting data from hospitals across different countries, we aim to:
* Identify how many infections are caused by multidrug-resistant bacteria.
* Understand how antibiotics (such as ceftriaxone, vancomycin, and carbapenems) act against these infections.
* Generate reports informing bacterial resistance patterns to help doctors make better patient treatment decisions.
What do we hope to achieve?
We hope the data we collect will help develop guidelines for patients with cirrhosis in Latin America. These guidelines will ensure that doctors use the most effective antibiotics based on real-time data from our region. This should improve patient outcomes and help prevent the spread of resistant bacteria.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Episodes of culture-confirmed bacterial infections
* Patients diagnosed with cirrhosis
* Infections diagnosed either at the time of hospital admission or during hospitalization
Exclusion Criteria:
* History of solid organ or hematopoietic stem cell transplantation
* Declined…
Inclusion Criteria:
* Episodes of culture-confirmed bacterial infections
* Patients diagnosed with cirrhosis
* Infections diagnosed either at the time of hospital admission or during hospitalization
Exclusion Criteria:
* History of solid organ or hematopoietic stem cell transplantation
* Declined to participate in the study
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
